Download PDF
Thromb Haemost 1993; 70(02): 313-319
DOI: 10.1055/s-0038-1649572
Original Articles
Fibrinolysis
Schattauer GmbH Stuttgart

A Variant of t-PA (T103N, KHRR 296-299 AAAA) that, by Bolus, Has Increased Potency and Decreased Systemic Activation of Plasminogen

Canio J Refino
1   The Department of Cardiovascular Research Genentech, Inc., South San Francisco, CA, USA
,
Nicholas F Paoni
1   The Department of Cardiovascular Research Genentech, Inc., South San Francisco, CA, USA
,
Bruce A Keyt
1   The Department of Cardiovascular Research Genentech, Inc., South San Francisco, CA, USA
,
Cheryl S Pater
1   The Department of Cardiovascular Research Genentech, Inc., South San Francisco, CA, USA
,
Julie M Badillo
1   The Department of Cardiovascular Research Genentech, Inc., South San Francisco, CA, USA
,
Florian M Wurm
2   The Department of Cell Culture R&D Genentech, Inc., South San Francisco, CA, USA
,
John Ogez
3   The Department of Recovery Process R&D, Genentech, Inc., South San Francisco, CA, USA
,
William F Bennett
1   The Department of Cardiovascular Research Genentech, Inc., South San Francisco, CA, USA
› Author Affiliations
Further Information

Publication History

Received 12 December 1992

Accepted after revision 17 February 1993

Publication Date:
04 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

In the accompanying paper, we reported that the properties of decreased plasma clearance rate, increased fibrin specificity, and resistance to inactivation by PAI-1 could be effectively combined in the t-PA variant T103N, KHRR 296-299 AAAA. In the current study we evaluated the in vivo efficacy of this variant as well as variants containing the individual mutations T103N and KHRR 296-299 AAAA. Plasma clearance and in vivo lysis of whole blood and platelet-rich clots were determined in a rabbit arterio-venous shunt model. The T103N containing variants were administered as an intravenous (i.v.) bolus. KHRR 296-299 AAAA and t-PA were infused i.v. over 90 min. The clearance rate of the KHRR 296-299 AAAA variant was similar to t-PA. However, the clearance of the T103N and T103N, KHRR 296-299 AAAA variants were 8 and 6-fold reduced, respectively. Potency of the variants relative to t-PA on whole blood clots ranged from 0.9 (T103N, KHRR 296-299 AAAA) to 1.7 (T103N). Relative potency on platelet-rich clots ranged from 2.4 (T103N) to 4.2 (T103N, KHRR 296-299 AAAA). Fibrinogen concentrations in rabbits 120 min after dosing with a 2.5 mg/kg bolus were: 24, 16, 82, and 77% of initial for t-PA; T103N; KHRR 296-299 AAAA; and T103N, KHRR 296-299 AAAA treatment groups, respectively. These results suggest that the T103N, KHRR 296-299 AAAA variant of t-PA, given as a bolus, could result in greater efficacy, particularly on refractory platelet-rich clots, without inducing the severe systemic lytic state produced by a bolus of a less fibrin specific variant.

 

  • References

  • 1 Collen D, Topol EJ, Tiefenbrunn AJ, Gold HK, Weisfeldt ML, Sobel BE, Leinbach RC, Brinker JA, Ludbrook PA, Yasuda I, Bulkley BH, Robison AK, Hutter Jr. AM, Bell WR, Spadard Jr. JJ, Khaw BA, Grossbard EB. Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo controlled trial. Circulation 1984; 70: 1012-1017
    CrossrefPubMedGoogle Scholar
  • 2 Topol EJ, Califf RM, George BS, Keriakes DJ. Lee KL for the TAMI Study Group, Insights derived from the thrombolysis and angioplasty in myocardial infarction (TAMI) trials. J Am Coll Cardiol 1988; 12: 24A-31A
    CrossrefPubMedGoogle Scholar
  • 3 Stump DC, Califf RM, Topol EJ, Sigmon K, Thornton D, Masek R, Andersen L, Collen D. the TAMI Study Group. Pharmacodynamics of thrombolysis with recombinant tissue-type plasminogen activator. Correlation with characteristics of and clinical outcomes in patients with acute myocardial infarction. Circulation 1989; 80: 1222-1230
    CrossrefPubMedGoogle Scholar
  • 4 TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial. N Eng J Med 1989; 320: 618-627
    CrossrefPubMedGoogle Scholar
  • 5 Topol EJ, George BS, Kereiakes DJ, Candela RJ, Abbottsmith CW, Stump DC, Boswick JM, Stack RS, Califf RM. Comparison of two dose regimens of intravenous tissue plasminogen activator for acute myocardial infarction. Am J Cardiol 1988; 61: 723-728
    CrossrefPubMedGoogle Scholar
  • 6 Neuhaus KL, Tebbe U, Gottwick M, Weber MAJ, Feuerer W, Haerer W, Praetorious F, Grosser KD, Huhmann W, Hoepp HW, Alber G, Sheikhzade A, Schneider B. Intravenous recombinant tissue plasminogen activator (rt-PA) and urokinase in acute myocardial infarction: results of the German Activator Urokinase Study (GAUS). J Am Coll Cardiol 1988; 12: 581-587
    CrossrefPubMedGoogle Scholar
  • 7 Neuhaus K-L, Feuerer W, Jeep-Tebbe S, Niederer W, Vogt A, Tebbe U. Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator. J Am Coll Cardiol 1989; 14: 1566-1569
    CrossrefPubMedGoogle Scholar
  • 8 Topol EJ. Ultrathrombolysis. J Am Coll Cardiol 1990; 15: 922-924
    CrossrefPubMedGoogle Scholar
  • 9 Tebbe U, Tanswell P, Seifried E, Feuerer W, Scholz K-H, Herrmann KS. Single-bolus injection of recombinant tissue-type plasminogen activator in acute myocardial infarction. Am J Cardiol 1989; 64: 448-453
    CrossrefPubMedGoogle Scholar
  • 10 Jang I-K, Gold HK, Ziskind AA, Fallon JT, Holt RE, Leinbach RC, May JW, Collen D. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator: A possible explanation for resistance to coronary thrombolysis. Circulation 1989; 79: 920-928
    CrossrefPubMedGoogle Scholar
  • 11 Refino CJ, Pater C, Hultgren B, Hotchkiss AJ. Platelet dependent inhibition of thrombolysis by Activase® rt-PA in a rabbit arteriovenous shunt. Fibrinolysis 1990; 4 (Suppl. 03) 57 (abstr)
    PubMedGoogle Scholar
  • 12 Levi M, Biemond BJ, van Zonneveld A-J, ten Cate JW, Pannekoek H. Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. Circulation 1992; 85: 305-312
    CrossrefPubMedGoogle Scholar
  • 13 Hotchkiss A, Refino C, DeGuzman L, Rigter B, Eisert W. A new pan species model for the measurement of in vivo thrombolysis. Thromb Haemostas 1987; 58: 377 (Abstr)
    PubMedGoogle Scholar
  • 14 Bliss CI. Confidence limits for measuring the precision of bioassays. Biometrics 1956; 12: 491-526
    CrossrefPubMedGoogle Scholar
  • 15 Mohler MA, Refino CJ, Chen SA, Chen AB, Hotchkiss AJ. D-Phe-Pro-Arg-chloromethylketone: its potential use in inhibiting the formation of in vitro artifacts in blood collected during tissue-type plasminogen activator thrombolytic therapy. Thromb Haemostas 1986; 56: 160-164
    PubMedGoogle Scholar
  • 16 Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol (Basel) 1957; 17: 237-240
    CrossrefPubMedGoogle Scholar
  • 17 Soria J, Soria C, Samama MA. A plasminogen assay using a chromogenic synthetic substrate: Results from clinical work and studies of thrombolysis. In: Chemical Fibrinolysis and Thrombolysis Vol 3. Davidson JF, MMS. Desnoyers PC. (eds) Raven Press; New York: 1978: 315-322
  • 18 Tiefenbrunn AJ, Graor RA, Robinson AK, Lucas FV, Hotchkiss A, Sobel BE. Pharmacodynamics of tissue-type plasminogen activator characterized by computer assisted simulation. Circulation 1986; 73: 1291-1299
    CrossrefPubMedGoogle Scholar
  • 19 Hotchkiss A, Refino CJ, Leonard CK, O’Connor JV, Crowley C, McCabe J, Tate K, Nakamura G, Powers D, Levinson A, Mohler M, Spellman MW. The influence of carbohydrate structure on the clearance of recombinant tissue-type plasminogen activator. Thromb Haemostas 1988; 60: 255-261
    PubMedGoogle Scholar
  • 20 Collen D, Stassen J, Larsen G. Pharmacokinetics and thrombolytic properties of deletion mutants of human tissue-type plasminogen activator in rabbits. Blood 1988; 71: 216-219
    PubMedGoogle Scholar
  • 21 Kalyan NK, Lee SG, Wilhelm J, Fu KP, Hum W-T, Rappaport R, Hartzell RW, Urbano C, Hung PP. Structure-function analysis with tissue-type plasminogen activator. Effect of deletion of NH2-terminal domains on its biochemical and biological properties. J Biol Chem 1988; 263: 3971-3978
    PubMedGoogle Scholar
  • 22 Fu KP, Lee S, Hum WT, Kalyan N, Rappaport R, Hetzel N, Hung PP. Disposition of a novel recombinant tissue plasminogen activator. Δ2-89 TPA, in mice. Thromb Res 1988; 50: 33-41
    PubMedGoogle Scholar
  • 23 Refino CJ, Hotchkiss AJ, Higgins DL, Mohler MA. The pharmacokinetics and circulatory metabolism of a long half-life mutant of rt-PA. Fibrinolysis 1988; 2 (Suppl. 01) 30 (Abstr)
    PubMedGoogle Scholar
  • 24 Larsen GR, Metzger M, Henson K, Blue Y, Horgan P. Pharmacokinetic and distribution analysis of variant forms of tissue-type plasminogen activator with prolonged clearance in rat. Blood 1989; 73: 1842-1850
    PubMedGoogle Scholar
  • 25 Browne MJ, Carey JE, Chapman CG, Tyrrell AWR, Entwisle C, Lawrence GMP, Reavy B, Dodd I, Esmail A, Robinson JH. A tissue-type plasminogen activator mutant with prolonged clearance in vivo. J Biol Chem 1988; 263: 1599-1602
    PubMedGoogle Scholar
  • 26 Lau D, Kuzma G, Wei C, Livingston DJ, Hsiung N. A modified human tissue plasminogen activator with extended half-life in vivo. Bio/Technology 1987; 5: 953-958
    CrossrefPubMedGoogle Scholar
  • 27 Lau D, Kuzma G, Wei C, Livingston DJ, Hsiung N. Erratum. Bio/ Technology 1988; 6: 734
    PubMedGoogle Scholar
  • 28 Martin U, von Möllendorf E, Akpan W, Kientsch-Engel R, Kaufmann B, Neugebauer G. Pharmacokinetic and hemostatic properties of the recombinant plasminogen activator BM 06.022 in healthy volunteers. Thromb Haemostas 1991; 66: 569-574
    PubMedGoogle Scholar
  • 29 Anderson S, Keyt B. Variants of plasminogen activators and processes for their production. In: International Patent Application No. PCT-US89-01947. 1989
  • 30 Ahem TJ, Morris GE, Barone KM, Horgan PG, Timony GA, Angus LB, Henson KS, Stoudemire JB, Langer-Safer PR, Larsen GR. Site-directed mutagenesis in human tissue plasminogen activator. J Biol Chem 1990; 265 (10) 5540-5545
    PubMedGoogle Scholar
  • 31 Gardell SJ, Duong LT, Diehl RE, York JD, Hare TR, Register RB, Jacobs JW, Dixon RAF, Friedman PA. Isolation, characterization, and cDNA cloning of a vampire bat salivary plasminogen activator. J Biol Chem 1989; 264: 17947-17952
    PubMedGoogle Scholar
  • 32 Gardell SJ, Ramjit DR, Stabilito II, Fujita T, Lynch JJ, Cuca GC, Jain D, Wang S, Tung J-S, Mark GE, Shebuski RJ. Effective thrombolysis without marked plasminemia after bolus intravenous administration of vampire bat salivary plasminogen activator in rabbits. Circulation 1991; 84: 244-253
    CrossrefPubMedGoogle Scholar
  • 33 Gardell SJ, Hare TR, Bergum PW, Cuca GC, O’Neill-Palladino L, Zavodny SM. Vampire bat salivary plasminogen activator is quiescent in human plasma in the absence of fibrin unlike human tissue plasminogen activator. Blood 1990; 76: 2560-2564
    PubMedGoogle Scholar
  • 34 Cambier P, van de Werf F, Larsen GR. Pharmacokinetics and thrombolytic properties of a nonglycosylated mutant of human tissue-type plasminogen activator, lacking the finger and growth factor domains, in dogs with copper coil-induced coronary artery thrombosis. J Cardiovasc Pharmacol 1988; 11: 468-472
    CrossrefPubMedGoogle Scholar
  • 35 Wu Z, van de Werf F, Stassen T, Mattsson C, Pohl G, Collen D. Pharmacokinetics and coronary thrombolytic properties of two human tissue-type plasminogen activator variants lacking the finger-like, growth factor-like, and first kringle domains (amino acids 6-173) in a canine model. J Cardiovasc Pharm 1990; 16: 197-203
    CrossrefPubMedGoogle Scholar
  • 36 Jackson CV, Crow VG, Craft TJ, Sundboom JL, Grinnell BW, Bobbitt JL, Burck PJ, Quay JF, Smith GF. Thrombolytic activity of a novel plasminogen activator, LY210825, compared with recombinant tissue-type plasminogen activator in a canine model of coronary artery thrombosis. Circulation 1990; 82: 930-940
    CrossrefPubMedGoogle Scholar
  • 37 Martin U, Fischer S, Kohnert U, Opitz U, Rudolph R, Sponer G, Stern A, Strein K. Thrombolysis with an escherichia-coli-produced recombinant plasminogen activator (BM 06.22) in the rabbit model of jugular vein thrombosis. Thromb Haemostas 1991; 65 (05) 560-564
    PubMedGoogle Scholar
  • 38 Martin U, Fischer S, Kohnert U, Rudolph R, Sponer G, Stern A, Strein K. Coronary thrombolytic properties of a novel recombinant plasminogen activator (BM 06.22) in a canine model. J Cardiovasc Pharmacol 1991; 18: 111-119
    CrossrefPubMedGoogle Scholar
  • 39 Refino CJ, Hultgren B, Hollenbach S, Hotchkiss AJ. Comparison of a bolus and a infusion dose regimen of recombinant tissue-type plasminogen activator (rt-PA) on the rate of thrombolysis in the rabbit jugular vein model (RJVM). Thromb Haemostas 1987; 58(1): 235 (Abstr)
    PubMedGoogle Scholar
  • 40 Stassen JM, Vanlinthout I, Kieckens L, Lijnen HR, Collen D. Thrombolysis with different rt-PA regimens in rabbits with experimental jugular vein thrombosis. Fibrinolysis 1990; 4 (Suppl. 03) 172 (Abstr)
    PubMedGoogle Scholar
  • 41 Hofmann KJ, Mayer EJ, Schultz LD, Socher SH, Reilly CF. Purification and characterisation of recombinant rabbit plasminogen activator inhibitor-1 expressed in saccharomyces cerevisiae. Fibrinolysis 1992; 6: 263-272
    PubMedGoogle Scholar
  • 42 Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, Bell WR, Knatternd G, Robertson TL, Terrin ML. for the Timi investigators. Thrombolysis in myocardial infarction (TIMI) trial-phase 1: Hemorrhagic manifestations and changes in plasma fibrinogen and fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988; 11: 1-11
    CrossrefPubMedGoogle Scholar
  • 43 Arnold AER, Brower RW, Collen D, van Es G-A, Lubsen J, Serruys PW, Simoons ML, Verstraete M. for the European Co-Operative Study Group for rt-PA. Increased serum levels of fibrinogen degradation products due to treatment with recombinant tissue-type plas-minogen activator for acute myocardial infarction are related to bleeding complications, but not to coronary patency. J Am Coll Cardiol 1989; 14: 581-588
    CrossrefPubMedGoogle Scholar
  • 44 Fennerty AG, Levine MN, Hirsh J. Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism. Chest 1989; 95: 885-975
    CrossrefPubMedGoogle Scholar
  • 45 Munkvad S, Jespersen J, Gram J, Kluft C. Depression of factor XII-dependent fibrinolytic activity characterizes patients with early myocardial reinfarction after recombinant tissue-type plasminogen activator therapy. JACC 1991; 18: 454-458
    CrossrefPubMedGoogle Scholar
  • 46 Tanswell P, Heinzei G, Greischel A, Krause J. Nonlinear pharmacokinetics of tissue-type plasminogen activator in three animal species and isolated rat liver. J Pharmacol Exp Ther 1990; 255 (01) 318-324
    PubMedGoogle Scholar